$NEO

Aunan Greg D (Chief Accounting Officer) sold 20,000 shares of NEOGENOMICS INC (NEO) at $16.07 ($0.32M total) on 2026-08-04.

BlackRock, Inc. filed an amended beneficial ownership report for NeoGenomics, Inc. common stock. BlackRock reported holding 20,358,331 shares, or 15.6% of the outstanding class. The filing says 19,688,877 shares have sole voting power and 20,358,331 shares have sole dispositive power, and notes iShares Core S&P Small-Cap ETF holds more than 5%.

NeoGenomics (NASDAQ: NEO) reported Q2 adjusted gross margin of 48.1% and adjusted EBITDA of $14.4 million. It raised 2026 revenue guidance to $802 million to $806 million and adjusted EBITDA to $56 million to $58 million. Management discussed RaDaR ST and PanTracer LBx reimbursement progress, NovaSeq X transitions, and a $316 million convertible note raise. Cash was $145.5 million.

Biotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.

Morgan Stanley research cited by the article says the median S&P 500 EPS surprise was 6% in Q1 2026, above the long-run ~5.5% average. FactSet research cited says firms with positive EPS surprises tend to keep outperforming after results. The article lists 28 companies that beat Wall Street EPS expectations, including Ford (EPS $0.66 vs $0.31), Bloom Energy (EPS $0.78 vs $0.37; revenue >$1B, +164% YoY), and Incyte (EPS $3.09 vs $0.94).

NeoGenomics (NEO) shares rose 15.8% after the company reported Q2 2026 adjusted EPS of $0.05 on revenue of $201.7 million, beating Wall Street forecasts of $0.03 and $197.3 million. NeoGenomics also raised full-year guidance to about $804 million revenue and $0.19 adjusted EPS.

NeoGenomics (NEO) reported Q2 2026 revenue of $201.7 million, up 11% year over year, with clinical revenue up 14% and NGS revenue up 26%. Adjusted gross margin rose to 48.1% and adjusted EBITDA increased to $14.4 million. Nonclinical/pharma revenue fell 26%. 2026 guidance was raised to $802-$806 million revenue and $56-$58 million adjusted EBITDA.

NeoGenomics (NASDAQ: NEO) reported Q2 CY2026 revenue of $201.7 million, up 11.2% year over year, exceeding Wall Street estimates by 2.2%. Non-GAAP EPS was $0.05, above consensus by $0.02. The company guided full-year revenue to about $804 million and expects EPS to rise from $0.15 to $0.29.

NEOGENOMICS INC (NEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a99-106302026earningsrelea.htm EX-99.1 Document Exhibit 99.1 NeoGenomics Reports Second Quarter 2026 Results Total revenue increased 11% YoY to $202 million Clinical services revenue grew 14%, with NGS revenue growth of 26% Company raises full-year 2026 revenue and adju

NeoGenomics (NASDAQ: NEO) is set to report Q2 earnings Tuesday. The company last quarter reported $186.7M revenue, up 11.1% year over year, with EPS in line and full-year revenue guidance meeting expectations. Analysts expect Q2 revenue growth of 8.8% y/y. NEO is down 2.5% over the past month, with an average analyst price target of $16.78 versus $13.89.